Subtype
Malignant Urinary System Neoplasm
CI-CAN-00001187Explore in graph →
887 active trials28 approved drugs109 evidence items
- NCIt
- C9297
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001187Explore in graph →
Clinical trials
3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (556)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00635726 | Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer | terminated | Phase 2 | 41 | Hellenic Oncology Research GroupOTHER | 1 | Oct 8, 2015 | clinicaltrials |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | terminated | Phase 2 | 4 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Oct 6, 2015 |
| clinicaltrials |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 17 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT00995488 | Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer | terminated | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 11, 2015 | clinicaltrials |
| NCT00601926 | Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 5 | Paul MonkOTHER | 1 | Jun 15, 2015 | clinicaltrials |
| NCT01374789 | PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer(PURO) | terminated | Phase 2 | 2 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT00933374 | Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma(RAD001) | terminated | Phase 2 | 28 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Mar 18, 2015 | clinicaltrials |
| NCT01720693 | Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy | terminated | Phase 2 | 3 | University Health Network, TorontoOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT00393796 | Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma | terminated | Phase 2 | 54 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 13, 2014 | clinicaltrials |
| NCT02013765 | A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer | terminated | Phase 2 | 5 | Hoffmann-La RocheINDUSTRY | 1 | Sep 25, 2014 | clinicaltrials |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jul 25, 2014 | clinicaltrials |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | terminated | Phase 2 | 49 | Queen Mary University of LondonOTHER | 1 | Jun 24, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | May 21, 2014 | clinicaltrials |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 15, 2014 | clinicaltrials |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 30 | University of ChicagoOTHER | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00176501 | Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer | terminated | Phase 2 | 3 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 1 | BayerINDUSTRY | 1 | Oct 11, 2013 | clinicaltrials |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 40 | University of ChicagoOTHER | 1 | Sep 5, 2013 | clinicaltrials |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | Accelerated Community Oncology Research NetworkOTHER | 1 | Jul 18, 2013 | clinicaltrials |
| NCT00516750 | Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and Cisplatin | terminated | Phase 2 | 100 | Kyoto UniversityOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 24, 2013 | clinicaltrials |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00009919 | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00087295 | S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium | terminated | Phase 2 | 6 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 2, 2012 | clinicaltrials |
| NCT01551407 | Detection of Bladder Tumors After 30 Min Instillation of Hexvix | terminated | Phase 2 | 38 | PhotocureINDUSTRY | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00243009 | Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery | terminated | Phase 2 | 1 | OHSU Knight Cancer InstituteOTHER | 1 | May 28, 2012 | clinicaltrials |
| NCT00100685 | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) | terminated | Phase 2 | 48 | AbbottINDUSTRY | 1 | Apr 27, 2012 | clinicaltrials |
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 12 | EndocyteINDUSTRY | 1 | Mar 8, 2012 | clinicaltrials |
| NCT00003640 | Transurethral Resection and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 73 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Mar 6, 2012 | clinicaltrials |
| NCT00003642 | Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer | terminated | Phase 2 | 43 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Mar 6, 2012 | clinicaltrials |
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 26, 2011 | clinicaltrials |
| NCT01215266 | Sorafenib in Urothelium Cancer of Bladder | terminated | Phase 2 | 98 | Association of Urologic Oncology (AUO)OTHER | 0 | Sep 8, 2011 | clinicaltrials |
| NCT00277316 | Study of XL999 in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 11 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 19, 2010 | clinicaltrials |
| NCT00323791 | Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer | terminated | Phase 2 | 100 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | terminated | Phase 2 | 16 | Genentech, Inc.INDUSTRY | 0 | Apr 10, 2009 | clinicaltrials |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 124 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 28, 2007 | clinicaltrials |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | terminated | Phase 2 | 36 | AttenuonINDUSTRY | 1 | Dec 6, 2007 | clinicaltrials |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | terminated | Phase 2 | 36 | Rennes University HospitalOTHER | 1 | Jan 2, 2006 | clinicaltrials |
Data updated 23 days agoSource updated Oct 8, 2015source: clinicaltrials